David D Khan1, Pernilla Lagerbäck2, Sha Cao3, Ulrika Lustig3, Elisabet I Nielsen4, Otto Cars2, Diarmaid Hughes3, Dan I Andersson3, Lena E Friberg4. 1. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden david.khan@farmbio.uu.se. 2. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 3. Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden. 4. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Abstract
OBJECTIVES: In silico pharmacokinetic/pharmacodynamic (PK/PD) models can be developed based on data from in vitro time-kill experiments and can provide valuable information to guide dosing of antibiotics. The aim was to develop a mechanism-based in silico model that can describe in vitro time-kill experiments of Escherichia coli MG1655 WT and six isogenic mutants exposed to ciprofloxacin and to identify relationships that may be used to simplify future characterizations in a similar setting. METHODS: In this study, we developed a mechanism-based PK/PD model describing killing kinetics for E. coli following exposure to ciprofloxacin. WT and six well-characterized mutants, with one to four clinically relevant resistance mutations each, were exposed to a wide range of static ciprofloxacin concentrations. RESULTS: The developed model includes susceptible growing bacteria, less susceptible (pre-existing resistant) growing bacteria, non-susceptible non-growing bacteria and non-colony-forming non-growing bacteria. The non-colony-forming state was likely due to formation of filaments and was needed to describe data close to the MIC. A common model structure with different potency for bacterial killing (EC50) for each strain successfully characterized the time-kill curves for both WT and the six E. coli mutants. CONCLUSIONS: The model-derived mutant-specific EC50 estimates were highly correlated (r(2) = 0.99) with the experimentally determined MICs, implying that the in vitro time-kill profile of a mutant strain is reasonably well predictable by the MIC alone based on the model.
OBJECTIVES: In silico pharmacokinetic/pharmacodynamic (PK/PD) models can be developed based on data from in vitro time-kill experiments and can provide valuable information to guide dosing of antibiotics. The aim was to develop a mechanism-based in silico model that can describe in vitro time-kill experiments of Escherichia coli MG1655WT and six isogenic mutants exposed to ciprofloxacin and to identify relationships that may be used to simplify future characterizations in a similar setting. METHODS: In this study, we developed a mechanism-based PK/PD model describing killing kinetics for E. coli following exposure to ciprofloxacin. WT and six well-characterized mutants, with one to four clinically relevant resistance mutations each, were exposed to a wide range of static ciprofloxacin concentrations. RESULTS: The developed model includes susceptible growing bacteria, less susceptible (pre-existing resistant) growing bacteria, non-susceptible non-growing bacteria and non-colony-forming non-growing bacteria. The non-colony-forming state was likely due to formation of filaments and was needed to describe data close to the MIC. A common model structure with different potency for bacterial killing (EC50) for each strain successfully characterized the time-kill curves for both WT and the six E. coli mutants. CONCLUSIONS: The model-derived mutant-specific EC50 estimates were highly correlated (r(2) = 0.99) with the experimentally determined MICs, implying that the in vitro time-kill profile of a mutant strain is reasonably well predictable by the MIC alone based on the model.
Authors: Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann Journal: Drugs Date: 2020-05 Impact factor: 9.546
Authors: Anders Thorsted; Eva Tano; Kia Kaivonen; Jan Sjölin; Lena E Friberg; Elisabet I Nielsen Journal: Antimicrob Agents Chemother Date: 2020-03-24 Impact factor: 5.191
Authors: Johanna Seeger; Sebastian Guenther; Katharina Schaufler; Stefan E Heiden; Robin Michelet; Charlotte Kloft Journal: Antibiotics (Basel) Date: 2021-05-21
Authors: Oskar Clewe; Linda Aulin; Yanmin Hu; Anthony R M Coates; Ulrika S H Simonsson Journal: J Antimicrob Chemother Date: 2015-12-24 Impact factor: 5.790
Authors: Muhammad W Sadiq; Elisabet I Nielsen; Dalia Khachman; Jean-Marie Conil; Bernard Georges; Georges Houin; Celine M Laffont; Mats O Karlsson; Lena E Friberg Journal: J Pharmacokinet Pharmacodyn Date: 2016-08-30 Impact factor: 2.745
Authors: Oskar Clewe; Alan Faraj; Yanmin Hu; Anthony R M Coates; Ulrika S H Simonsson Journal: J Pharmacokinet Pharmacodyn Date: 2020-06-01 Impact factor: 2.745